Cargando…

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects

Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4. This study aimed to evaluate the pharmacokinetics (PK) of atorvastatin and safety when atorvastatin was administered alone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hwang, Sejung, Ko, Jae-Wook, Lee, Heechan, Kim, Seokuee, Kim, Bongtae, Song, Geun Seog, Kim, Jungryul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632694/ https://www.ncbi.nlm.nih.gov/pubmed/34867368 http://dx.doi.org/10.3389/fphar.2021.754849

Ejemplares similares

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
por: Han, Sungpil, et al.
Publicado: (2023)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2018)

Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study
por: Kim, Seokuee, et al.
Publicado: (2019)

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects
por: Kim, Jung-Ryul, et al.
Publicado: (2019)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
por: Woo, Hye In, et al.
Publicado: (2017)

Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
por: Langeskov, Emilie K., et al.
Publicado: (2022)

Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers
por: Kim, Seokuee, et al.
Publicado: (2018)

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects
por: Kim, Serim, et al.
Publicado: (2022)

Pharmacokinetic Interaction of Green Rooibos Extract With Atorvastatin and Metformin in Rats
por: Patel, Oelfah, et al.
Publicado: (2019)

Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan
por: Sugimoto, Mitsushige, et al.
Publicado: (2019)

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
por: Kim, Joon Sung, et al.
Publicado: (2023)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
por: Ghim, Jong-Lyul, et al.
Publicado: (2019)

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori
por: Zhang, Zinan, et al.
Publicado: (2023)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects
por: Patiño-Rodríguez, Omar, et al.
Publicado: (2015)

Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions
por: Choi, Young-Kyung, et al.
Publicado: (2017)

Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
por: Patiño-Rodríguez, Omar, et al.
Publicado: (2014)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

Evaluation of commonly used cardiovascular drugs in inhibiting vonoprazan metabolism in vitro and in vivo
por: Wang, Yiran, et al.
Publicado: (2022)

Population Pharmacokinetic Model of AST-001, L-Isomer of Serine, Combining Endogenous Production and Exogenous Administration in Healthy Subjects
por: Lee, Soyoung, et al.
Publicado: (2022)

Prediction of the Drug–Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
por: Wei, Zhuodu, et al.
Publicado: (2023)

Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages
por: Han, Gong-Ho, et al.
Publicado: (2023)

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
por: Sun, Haiying, et al.
Publicado: (2016)

Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon?
por: Abadi, Amin Talebi Bezmin, et al.
Publicado: (2019)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Pharmacokinetics of marbofloxacin after intravenous and intramuscular administration in Hanwoo, Korean native cattle
por: BELEW, Sileshi, et al.
Publicado: (2014)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3i7e9to3nbuejs9vepf3ed2p4e